Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06173219 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.

StatusRecruiting
PhasePhase 1/2
Started2025-08-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 27, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-02-25
Study Identification, Study Status, Oversight v2
Primary completion date2025-05-31→2026-07-31
Completion date2025-08-31→2026-12-31
Start date2023-12-15→2025-08-01
Study titlerevised
Safety and Efficacy of Radiotherapy Combined Withwith Immunotherapy for Advanced Malignant Tumors.
2023-12-17
Not Yet Recruiting→Recruiting Study Status, Study Description, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites0→1
Eligibility criteria+37 characters
[...] ons must be measured; no contraindications to radiotherapy; EGOGEastern Cooperative Oncology Group (ECOG) score: 0-2 points, and life expectancy >3 months; important [...] formed consent. Exclusion Criteria: no suitable lesions for radiotherayradiotherapy, or the limit of important organs at risk could not be met; [...] cal conditions (such as pregnancy or breastfeeding status); patientsspatients who are known to be allergic to the drugs used in this stud [...]
Study description+15 characters
[...] ow-dose radiotherapy (LDRT) for advanced tumors. Therefore, wethe investigators designed a new radioimmunotherapy regimen, including SBRT, [...]
2023-12-07
Original filing
The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance. The main questions it aims to answer is: the safety and efficacy of the new regimen for advanced multiple metastatic solid tumors standard treatment failure/drug resistance, and explore the impact on immune function. Participants will receive the combination of radiotherapy and immunotherapy.
Trial Details
NCT Number NCT06173219
Lead Sponsor China-Japan Friendship Hospital
Conditions Advanced Solid Tumor
Enrollment 38 participants
Start Date 2025-08-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-27